Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Net Income
(23,848)
(77,211)
(117,042)
(630,210)
Operating Activities, Cash Flows Provided By or Used In
Depreciation
105,300
95,671
87,861
96,912
Changes In Accounts Receivables
(37,852)
(54,274)
(25,256)
(51,483)
Changes In Assets and Liabilities
(101,092)
(49,420)
(93,963)
(160,276)
Changes In Inventories
(107,554)
(23,747)
(96,890)
(64,512)
Changes In Other Operating Activities
213,308
129,189
236,533
581,732
Total Cash Flow From Operating Activities
48,262
20,208
(8,757)
(227,837)
Investing Activities, Cash Flows Provided By or Used In
Capital Expenditures
(163,406)
(144,620)
(199,219)
(148,380)
Investments
108,188
358,981
(229,487)
(332,180)
Other Cash flows from Investing Activities
24,192
49,990
123,247
(3,487)
Total Cash Flows From Investing Activities
(31,026)
264,351
(305,459)
(484,047)
Financing Activities, Cash Flows Provided By or Used In
Dividends Paid
--
--
--
--
Sale/Purchase of Stock
--
0
0
712,938
Net Borrowings
(5,087)
(374,953)
481,687
0
Other Cash Flows from Financing Activities
(69,587)
(13,054)
25,458
14,170
Total Cash Flows From Financing Activities
(74,674)
(388,007)
507,145
727,108
Effect Of Exchange Rate Changes
902
(598)
(3,231)
(3,934)
Change In Cash and Cash Equivalents
(57,438)
(103,448)
192,929
15,224

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information